Hyperfine (NASDAQ: HYPR) revenue
Hyperfine reported revenue of $13.6m for fiscal 2025, 5.2% more than in fiscal 2024 ($12.9m). Since fiscal 2020 its revenue has grown by 4,513.3%, an average growth of 115.2% a year.
Hyperfine has grown its revenue for 5 years in a row, and fiscal 2025 is the highest of its 6 fiscal years on record.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $13.6m | +5.2% | −$37.1m | −273.4% |
| 2024 | $12.9m | +16.8% | −$43.2m | −335.3% |
| 2023 | $11.0m | +61.9% | −$48.1m | −436.1% |
| 2022 | $6.8m | +355.5% | −$73.9m | −1,084.2% |
| 2021 | $1.5m | +408.8% | −$64.9m | −4,336.1% |
| 2020 | $0.3m | — | −$23.5m | −7,990.1% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Hyperfine revenue compared with its sector
By revenue for its latest fiscal year, Hyperfine ranks 362nd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Hyperfine, 5.2%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 360th | Opus Genetics | $14.2m | 29.1% |
| 361st | Arbutus Biopharma | $14.1m | 128.2% |
| 362nd | Hyperfine | $13.6m | 5.2% |
| 363rd | Tonix Pharmaceuticals | $13.1m | 29.8% |
| 364th | Prelude Therapeutics | $12.1m | 73.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Hyperfine
- How much revenue did Hyperfine make in fiscal 2025?
- Hyperfine reported revenue of $13.6m for fiscal 2025, compared with $12.9m in fiscal 2024.
- How much has the revenue of Hyperfine grown?
- Between fiscal 2020 and fiscal 2025 it went from $0.3m to $13.6m: 4,513.3% more, an average growth of 115.2% a year.
- What was the best year for revenue at Hyperfine?
- Of its last 6 fiscal years, fiscal 2025, with $13.6m.
- Where does Hyperfine rank in its sector by revenue?
- It ranks 362nd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Hyperfine come from?
- From the annual report (Form 10-K) that Hyperfine files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Hyperfine files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Hyperfine: the Hyperfine page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.